Goldman Sachs (NYSE:GS) analyst Goldman Sachs maintained a Hold rating on Baxter International (NYSE:BAX) on Tuesday, setting a price target of $80, which is approximately 4.88% above the present share price of $76.28.
expects Baxter International to post earnings per share (EPS) of $0.59 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Baxter International, with an average price target of $89.71.
The analysts price targets range from a high of $105 to a low of $80.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $3.1 billion and a net profit of $421 million. The company's market cap is $38.13 billion.
According to TipRanks.com, Goldman Sachs analyst Goldman Sachs is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 10.1% and a 58.53% success rate.
Founded in 1931 and based in Illinois, Baxter International, Inc. provides a portfolio of healthcare products. The company focuses on transformative innovation to deliver smarter, more personalized care for patients and providers. It operates through six global businesses: Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery and Acute Therapies.